Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

Dongiovanni, Paola, Petta, Salvatore, Maglio, Cristina, Fracanzani, Anna Ludovica, Pipitone, Rosaria, Mozzi, Enrico, Motta, Benedetta Maria, Kaminska, Dorota +20 more·2015·Hepatology
DOI 10.1002/hep.27490

Cited by (532)

Items 301–400 of 532

  1. Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis
    Bharaj, Inderjeet Singh, Brar, Ajit Singh, Kahlon, Jasraj, Singh, Anmol, Hotwani, Priya, Kumar, Vikash, Sohal, Aalam, Batta, Akash · 2025 · World Journal of Cardiology
  2. The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
    Muhammad Shahzeb Khan, Syed Sarmad Javaid, Amreen M. Dinani, Kara Wegermann, Ambarish Pandey, Ankeet S. Bhatt, Mark Dhinesh Muthiah, Harriette G.C. Van Spall, Faiez M. Zannad, Javed Butler et al. · 2025 · Journal of the American College of Cardiology
  3. Genetic Variation in the Mitochondrial Glycerol‐3‐Phosphate Acyltransferase Is Associated With Liver Injury
    Aaron Hakim, Matthew R. Moll, Joseph Brancale, Jiangyuan Liu, Jessica Ann Lasky-Su, Edwin K. Silverman, Sílvia Vilarinho, Zhenghui Gordon Jiang, Yered H. Pita-Juárez, Ioannis S. Vlachos et al. · 2021 · Hepatology
  4. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)
    Giada Sebastiani, Keyur Patel, Vlad Ratziu, Jordan J. Feld, Brent A. Neuschwander‐Tetri, Massimo Pinzani, Salvatore Petta, Annalisa Berzigotti, Peter P. Metrakos, Naglaa H. Shoukry et al. · 2021 · Canadian Liver Journal
  5. The mitochondrial amidoxime reducing component—from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target
    Michel A. Struwe, Axel J. Scheidig, Bernd Clement · 2023 · Journal of Biological Chemistry
  6. Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
    Georgiana-Emmanuela Gîlcă-Blanariu, Daniela Simona Budur, Dana Mitrică, Elena Gologan, Oana Timofte, Gheorghe Gh Bălan, VASILE-ANDREI OLTEANU, Gabriela Ștefănescu · 2023 · Metabolites
  7. From MASH to HCC: the role of Gas6/TAM receptors
    Daria Apostolo, Luciana L. Ferreira, Federica Vincenzi, Nicole Vercellino, Rosalba Minisini, Federico Latini, Barbara Ferrari, Michela Emma Burlone, Mario Pirisi, Mattia Bellan · 2024 · Frontiers in Immunology
  8. Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction–Associated Steatotic Liver Diseases: A Pathway to Precision Medicine
    Xiang Zhang, Kyong‐Mi Chang, Jun Qing Yu, Rohit Seth Loomba · 2025 · Annual Review of Pathology Mechanisms of Disease
  9. Alcoholic Liver Disease
    Mack C. Mitchell, Gyöngyi Szabó · 2017 · Wiley eBooks
  10. Liver Steatosis: A Marker of Metabolic Risk in Children
    Costanza Renata Neri, Serena Scapaticci, Francesco Chiarelli, Cosimo Giannini · 2022 · International Journal of Molecular Sciences
  11. Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
    Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Alexander Spitz, Amon Asgharpour, Mohammad Shadab Siddiqui, Laurence S. Sperling, Arshed Ali Quyyumi, Anurag Mehta · 2024 · Diabetes Research and Clinical Practice
  12. TM 6 SF 2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C
    Salvatore Petta, Marcello Fabio Maida, Stefania Grimaudo, Rosaria Maria Pipitone, Fabio Salvatore Macaluso, Daniela Cabibi, Calogero Cammà, Vito Di Marco, Sandro Sferrazza, Antonio Craxı̀ · 2015 · Liver International
  13. The Genetics of Clinical Liver Diseases: Insight into the TM6SF2 E167K Variant
    Xiaoyu Zhang, Shousheng Liu, Quanjiang Dong, Yongning Xin, Shiying Xuan · 2018 · Journal of Clinical and Translational Hepatology
  14. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes
    Giandomenico Bisaccia, Fabrizio Ricci, Cesare Mantini, Claudio Tana, Gian Luca Romani, Cosima Schiavone, Sabina Gallina · 2020 · SAGE Open Medicine
  15. A PNPLA3 Polymorphism Confers Lower Susceptibility to Incident Diabetes Mellitus in Subjects With Nonalcoholic Fatty Liver Disease
    Seoil Moon, Goh Eun Chung, Sae Kyung Joo, Jeong Hwan Park, Mee Soo Chang, Ji Won Yoon, Bo Kyung Koo, Won Kyum Kim · 2021 · Clinical Gastroenterology and Hepatology
  16. Genetic variants associated with metabolic dysfunction‐associated fatty liver disease in western China
    Shenling Liao, Kang An, Zhi Liu, He He, Zhenmei An, Qiaoli Su, Shuangqing Li · 2022 · Journal of Clinical Laboratory Analysis
  17. A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption
    Rosellina Margherita Mancina, Flaminia Ferri, Alessio Farcomeni, Antonio Molinaro, Angela Maffongelli, Monica Mischitelli, Edoardo Poli, Lucia Parlati, Maria Antonella Burza, Adriano De Santis et al. · 2019 · The Application of Clinical Genetics
  18. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
    Eleftheria Galatou, Elena A. Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis · 2022 · Antioxidants
  19. Hepatic COX1 loss leads to impaired autophagic flux and exacerbates nonalcoholic steatohepatitis
    Qian Yu, Chang Li, Qinghui Niu, Jigang Wang, Zhaodi Che, Ke Lei, He Ren, Boyi Ma, Yixing Ren, Pingping Luo et al. · 2023 · Acta Pharmaceutica Sinica B
  20. Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases
    Daqing Zhang, Zhen Mi, Jiya Peng, Tiangui Yang, Yuze Han, Yujia Zhai, Chenliang Song, Xianzhuo Teng, Wei Sun, Jing Guo et al. · 2023 · Journal of Cardiovascular Pharmacology
  21. Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD
    Paola Dongiovanni, Marica Meroni, Salvatore Petta, Miriam Longo, Anna Alisi, Giorgio Soardo, Luca V. C. Valenti, Luca Miele, Stefania Grimaudo, Grazia Pennisi et al. · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
  22. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease
    Wan-Ying Xue, Li Rita Zhang, Chuanmiao Liu, Yu Gao, Shujing Li, Ziyou Huai, Jing Dai, Yuanyuan Wang · 2022 · Expert Review of Gastroenterology & Hepatology
  23. The impact of transmembrane 6 superfamily 2 (TM6SF2) rs58542926 on liver-related events in patients with advanced chronic liver disease
    Lorenz Balcar, Bernhard Scheiner, Markus Urheu, Patrick Weinberger, Rafael Paternostro, Benedikt Simbrunner, Georg Semmler, Claudia Willheim, Matthias Pinter, Péter Ferenci et al. · 2023 · Digestive and Liver Disease
  24. Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease
    Zhewen Ren, Anke Wesselius, Coen D.A. Stehouwer, Martijn C.G.J. Brouwers · 2023 · Endocrinology and Metabolism Clinics of North America
  25. Correlation between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction in non-obese adults: a cross-sectional study
    Fangyuan Cong, Luying Zhu, Lihua Deng, Qian Xue, Jingtong Wang · 2023 · BMC Gastroenterology
  26. Transmembrane 6 superfamily member 2 167K allele improves renal function in children with obesity
    Pierluigi Marzuillo, Anna Di Sessa, Grazia Cirillo, Giuseppina Rosaria Umano, Marcella Pedullà, Angela La Manna, Stefano Guarino, Emanuele Miraglia del Giudice · 2020 · Pediatric Research
  27. Type 2 diabetes sex-specific effects associated with E167K coding variant in TM6SF2
    Yanbo Fan, Brooke N. Wolford, Haocheng Lu, Wenying Liang, Jinjian Sun, Wei Zhou, Oren Rom, Anubha Mahajan, Ida L. Surakka, Sarah E. Graham et al. · 2021 · iScience
  28. Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease
    Qingfeng Sun, Liang‐Jie Tang, Mingjie Wang, Pei‐Wu Zhu, Yangyang Li, Hong‐Lei Ma, Ou‐Yang Huang, Liang L. Hong, Gang Li, Christopher D. Byrne et al. · 2022 · Frontiers in Medicine
  29. Mechanism and therapeutic strategy of hepatic TM6SF2-deficient non-alcoholic fatty liver diseases via in vivo and in vitro experiments
    Zuyin Li, Gang Wu, Chen Qiu, Zhi-Jie Zhou, Yupeng Wang, Guohe Song, Chao Xiao, Xin Zhang, Guilong Deng, Ruitao Wang et al. · 2022 · World Journal of Gastroenterology
  30. Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study
    Anna Viitasalo, Jussi Pihlajamäki, Jussi Paananen, Mustafa Atalay, Virpi Lindi, Timo Antero Lakka · 2016 · Pediatric Research
  31. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum
    Federica Tavaglione, Giovanni Targher, Luca V. C. Valenti, Stefano Romeo · 2020 · Endocrinology Diabetes & Metabolism
  32. The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response
    Curtis Kent Argo, Yoshihiro Ikura, Carolin Lackner, Stephen Hugh Caldwell · 2015 · Hepatology
  33. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
    Atul Deep Bali, Akiva Rosenzveig, William H. Frishman, Wilbert S. Aronow · 2023 · Cardiology in Review
  34. Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV—Limitations on Antiretroviral Therapy Selection
    Georgios Kalopitas, Konstantinos Arvanitakis, Οlga Tsachouridou, Konstantinos Malandris, Theocharis Koufakis, Symeon Metallidis, Georgios S. Germanidis · 2024 · Life
  35. Metabolic Associated Fatty Liver Disease in Children—From Atomistic to Holistic
    Cristina Oana Mărginean, Lorena Elena Meliţ, Maria Oana Săsăran · 2021 · Biomedicines
  36. Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
    Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa · 2022 · World Journal of Clinical Pediatrics
  37. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease
    Zhenghui Gordon Jiang, Elliot B. Tapper, Mi-Sung Kim, Margery A. Connelly, Sarah A. Krawczyk, Eric U. Yee, Mark A. Herman, Kenneth Jay Mukamal, Michelle Lai · 2017 · Journal of Clinical Gastroenterology
  38. TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD
    Giovanni Musso, Maurizio Cassader, Elena Paschetta, Roberto Gambino · 2015 · Journal of Hepatology
  39. A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation
    Yanhao Qiu, Juan Carlos Laguna, Marta Alegret, Laia Vilà · 2026 · Nutrients
  40. The many pathways driving liver inflammation in MASH
    Herbert Tilg, Timon Erik Adolph, Stefano Romeo, Rohit Seth Loomba · 2026 · Cell Metabolism
  41. Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis
    Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Ivanivna Kamyshna, Sandor George Vari, Oleksandr Kamyshnyi · 2023 · Viruses
  42. Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
    Saumya Madushani Samarasinghe, Asanka Sudeshini Hewage, Rohan Chaminda Siriwardana, Kamani Hemamala Tennekoon, Madunil Anuk Niriella, Sumadee De Silva · 2023 · Egyptian Journal of Medical Human Genetics
  43. Mitochondria at the Crossroads: Linking the Mediterranean Diet to Metabolic Health and Non-Pharmacological Approaches to NAFLD
    Giovanna Mercurio, Antonia Giacco, Nicla Scopigno, Michela Vigliotti, Fernando Goglia, Federica Cioffi, Elena Silvestri · 2025 · Nutrients
  44. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis
    Monica A. Tincopa · 2020 · Endocrinology Diabetes & Metabolism
  45. Mortality in Patients With Genetic and Environmental Risk of Liver Disease
    Carolin Victoria Schneider, Malin Fromme, Kai Markus Schneider, Tony Bruns, Pavel Strnad · 2021 · The American Journal of Gastroenterology
  46. Potential Therapeutic Targets and Promising Agents for Combating NAFLD
    Atsushi Umemura, Seita Kataoka, Keiichiro Okuda, Yuya Seko, Kanji Yamaguchi, Michihisa Moriguchi, Takeshi Okanoue, Yoshito Itoh · 2022 · Biomedicines
  47. Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events
    Sara Saki, Nader Saki, Hossein Poustchi, Reza Malekzadeh · 2020 · Middle East Journal of Digestive Diseases
  48. PNPLA3 gene polymorphism is associated with liver steatosis in children with Down syndrome
    Diletta Valentini, Antonella Mosca, Chiara Di Camillo, Annalisa Crudele, Maria Rita Sartorelli, Vittorio Scoppola, Luigi Tarani, Alberto Villani, Massimiliano Raponi, Antonio Novelli et al. · 2020 · Nutrition Metabolism and Cardiovascular Diseases
  49. Pediatric Non‐Alcoholic Fatty Liver Disease Is Affected by Genetic Variants Involved in Lifespan/Healthspan
    Annalisa Crudele, Serena Dato, Oriana Lo Re, Andrea Maugeri, Paola Sanna, Sebastiano Giallongo, Jude A. Oben, Nadia Panera, Francesco De Rango, Antonella Mosca et al. · 2021 · Journal of Pediatric Gastroenterology and Nutrition
  50. Novel genes in LDL metabolism – a comprehensive overview
    Mette Christoffersen, Anne Tybjærg‐Hansen · 2015 · Current Opinion in Lipidology
  51. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease
    Christopher J. Danford, Margery A. Connelly, IRINA Y. SHALAUROVA, Mi-Sung Kim, Mark A. Herman, Imad Ahmad Nasser, James D. Otvos, Nezam H. Afdhal, Zhenghui Gordon Jiang, Michelle Lai · 2018 · Hepatology Communications
  52. Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials
    Álvaro Díaz‐González, Víctor Sapena, Loreto Boix, Mercè Brunet, Ferràn Torres, Neus Llarch, Esther Samper, Olga Millán, Josep Corominas, Gemma Iserte et al. · 2020 · Liver International
  53. Nonalcoholic fatty liver disease and its prognosis associates with shorter leucocyte telomeres in a 21-year follow-up study
    Arto Korkiakoski, Aki Juhani Käräjämäki, Justiina Ronkainen, JUHA P. AUVINEN, Jokke Hannuksela, Y. Antero Kesäniemi, Olavi H. Ukkola · 2022 · Scandinavian Journal of Clinical and Laboratory Investigation
  54. Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
    Emiliano Barbieri, Nicola Santoro, Giuseppina Rosaria Umano · 2023 · Frontiers in Endocrinology
  55. Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key
    Marta Alonso‐Peña, María Del Barrio, Ana Peleteiro‐Vigil, Carolina Jiménez-González, Álvaro Santos‐Laso, M. Arias, Paula Iruzubieta, Javier Crespo · 2023 · International Journal of Molecular Sciences
  56. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China
    Lizhen Chen, Hongyun Ding, Shousheng Liu, Qun Liu, Xiangjun Jiang, Yongning Xin, Shiying Xuan · 2019 · Lipids in Health and Disease
  57. The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis
    Cora Freund, Arne Wahlers, Nima Haji Begli, Yvonne Leopold, Petra Klöters-Plachky, Arianeb Mehrabi, Isabelle Mohr, Julia Sander, Christian Rupp, Daniel Nils Gotthardt et al. · 2020 · Clinics and Research in Hepatology and Gastroenterology
  58. Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis
    Stephan Buch, Aneesh Sharma, Eleanor M. Ryan, Christian Datz, William J. Griffiths, Michael J. Way, Thomas M. W. Buckley, John Denis Ryan, Stephen F. Stewart, Callum Wright et al. · 2021 · Alimentary Pharmacology & Therapeutics
  59. TM6SF2 rs58542926 Polymorphism is not Associated With Risk of Steatosis or Fibrosis in Chilean Patients With Chronic Hepatitis C
    Alvaro M. Urzua, Gabriel Mezzano P., Javier Brahm, Jaime Poníachik, Julio Miranda, Dante Cáceres, Laura E. Carreño, Mauricio Venegas · 2017 · Hepatitis Monthly
  60. Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach
    Helen Ye Rim Huang, Cecilia Vitali, David Zhang, Nicholas J. Hand, Michael C. Phillips, Kate Townsend Creasy, Eleonora Scorletti, Joseph Park, Kai Markus Schneider, Daniel James Rader et al. · 2024 · JHEP Reports
  61. Deciphering the liver enigma: distinguishing drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease—a comprehensive narrative review
    Miren García‐Cortés, Juan Pedro Toro-Ortiz, Alberto García-García · 2023 · Exploration of Digestive Diseases
  62. Novel insights into metabolic‐associated steatotic liver disease preclinical models
    Rocío Montero‐Vallejo, Douglas Maya‐Miles, Javier Ampuero, Franz Martı́n, Manuel Romero‐Gómez, Rocío Gallego‐Durán · 2024 · Liver International
  63. MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk
    Alaa Mohamed Mostafa, Ziyan Pan, Ming‐Lung Yu, Necati Örmecı, Yasser Mahrous Fouad, Mohammed Eslam · 2025 · Hepatic Medicine Evidence and Research
  64. Common Pathogenetic Pathways of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Charalampos Giannopoulos, Ioanna G. Tzima, Nikolaοs Tentolouris, Ioannis Vasileiadis · 2023 · Current Diabetes Reviews
  65. Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice
    Saleh A. Alqahtani, Jörn Markus Schattenberg · 2021 · Expert Review of Molecular Diagnostics
  66. Current approaches to diagnosing and treating nonalcoholic fatty liver disease
    Е. Л. Никонов, Aksenov Va · 2018 · Russian Journal of Preventive Medicine
  67. Increased circulating adiponectin in males with chronic HCV hepatitis
    Elena Canavesi, Marianna Porzio, Massimiliano Ruscica, Raffaela Rametta, Chiara Macchi, Serena Pelusi, Anna Ludovica Fracanzani, Paola Dongiovanni, Silvia Rossana Fargion, Paolo Magni et al. · 2015 · European Journal of Internal Medicine
  68. The Association of Hypolipidemia and Hyperlipidemia with Non-Alcoholic Fatty Liver Disease in Obese Children
    İlhan Hazer · 2020 · Türk Pediatri Arşivi
  69. NAFLD and cardiovascular disease
    Elisabete Martins, Ana Beatriz Furtado De Oliveira · 2018 · Porto Biomedical Journal
  70. Perturbation of TM6SF2 Expression Alters Lipid Metabolism in a Human Liver Cell Line
    Asmita Pant, Yue Chen, Annapurna Kuppa, Xiaomeng Du, Brian D. Halligan, Elizabeth K. Speliotes · 2021 · International Journal of Molecular Sciences
  71. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
    E Fassio, Fernando Javier Barreyro, M Soledad Pérez, Diana Dávila, Graciela Landeira, Gisela Gualano, Gabriela Ruffillo · 2022 · World Journal of Hepatology
  72. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models
    M. Longo, M. Meroni, Veronica Erconi, Fabrizia Carli, Chiara Macchi, Francesco Fortunato, Dario Ronchi, Silvia Sabatini, Erika Paolini, Emilia Rita De Caro et al. · 2021 · Digestive and Liver Disease
  73. Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level
    Pablo Gabriel-Medina, Roser Ferrer, Andreea Ciudin, Salvador Augustín, Jesús Rivera‐Esteban, Juan Manuel Pericàs, David M. Selva, Francisco Rodríguez‐Frias · 2023 · Internal and Emergency Medicine
  74. Non-alcoholic fatty liver infiltration in children: an underdiagnosed evolving disease
    Flora Tzifi, Andreas Fretzayas, George Panagiotis Chrousos, Christina Kanaka‐Gantenbein · 2019 · HORMONES
  75. Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges.
    Arash Dooghaie Moghadam, Pegah Eslami, Niloofar Razavi-Khorasani, Bobak Moazzami, Farbod Zahedi Tajrishi, Ermia Farokhi, Kamyab Makhdoomi Sharabiani, Alireza Mansour-Ghanaei, Azim Mehrvar, Morteza Aghajanpoor Pasha et al. · 2020 · PubMed Central
  76. New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer
    Xiaoxiao Jiang, Hui Qian, Wen‐Xing Ding · 2021 · Hepatology
  77. A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
    Alajos Pár, István Wittmann, Gabriella Pár · 2022 · Orvosi Hetilap
  78. Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease
    Peter Saliba‐Gustafsson, Jennifer Härdfeldt, Matteo Pedrelli, Paolo Parini · 2025 · International Journal of Molecular Sciences
  79. Associations between metabolic dysfunction-associated fatty liver disease and atherosclerotic cardiovascular disease
    Wen Wen, Huahao Fan, Shenghui Zhang, Siqi Hu, Chen Chen, Jiake Tang, Yao You, Chunyi Wang, Jie Li, Lin Luo et al. · 2024 · The American Journal of the Medical Sciences
  80. Genetics in liver diseases: From diagnostics to precise therapy
    Susanne Nicole Weber, Frank Lammert · 2017 · Clinical Liver Disease
  81. Association of Bright Liver with the PNPLA3 I148M Gene Variant in 1-year-old Toddlers
    Giorgio Bedogni, Giuseppe De Matteis, Marta Fabrizi, Anna Alisi, Annalisa Crudele, Fabrizio Pizzolante, Fabrizio Signore, Bruno Dallapiccola, Valério Nobili, Melania Manco · 2019 · The Journal of Clinical Endocrinology & Metabolism
  82. Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
    Francesca Terracciani, Andrea Falcomatà, Paolo Gallo, Antonio Picardi, Umberto Vespasiani Gentilucci · 2022 · Journal of Physiology and Biochemistry
  83. Genetic Markers Predisposing to Nonalcoholic Steatohepatitis
    Aalam Sohal, Hunza Chaudhry, Kris V. Kowdley · 2023 · Clinics in Liver Disease
  84. PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis
    Marica Meroni, Paola Dongiovanni · 2023 · International Journal of Molecular Sciences
  85. Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease
    Quentin Mark Anstee, Christopher Paul Day · 2018 · Elsevier eBooks
  86. Genetic variants in the MTHFR are not associated with fatty liver disease
    Antonio De Vincentis, Rosellina Margherita Mancina, Jussi Pihlajamäki, Ville Männistö, Salvatore Petta, Paola Dongiovanni, Anna Ludovica Fracanzani, Luca V. C. Valenti, Federica Tavaglione, Stefano Romeo et al. · 2020 · Liver International
  87. Editorial: new insights into the relationship between the intestine and non‐alcoholic fatty liver—is “fatty gut” involved in disease progression?
    Luca V. C. Valenti, Stefano Romeo · 2017 · Alimentary Pharmacology & Therapeutics
  88. Nonalcoholic Fatty Liver Disease
    Marie Boyle, Quentin Mark Anstee · 2019
  89. Fatty Liver Disease
    DINA G. TINIAKOS, Quentin Mark Anstee, Elizabeth M. Brunt, Alastair D. Burt · 2023 · Elsevier eBooks
  90. TM6SF2-rs58542926 Genotype Has Opposing Effects on Incidence of Hepatic and Cardiac Events in a Community Cohort
    Vincent Lingzhi Chen, Antonino Oliveri, Chinmay Raut, Yanhua Chen, Kelly C. Cushing, Elizabeth K. Speliotes · 2024 · The American Journal of Gastroenterology
  91. Cardiovascular Manifestations of Patients with Non-Alcoholic Fatty Liver Disease
    Vlad Pădureanu, Mircea-Cătălin Forțofoiu, Mircea Pîrșcoveanu, Rodica Pădureanu, D Rădulescu, Ionuţ Donoiu, Denisa Floriana Vasilica Pîrșcoveanu · 2025 · Metabolites
  92. MetALD: Genetic Factors and Clinical Outcomes
    Mads Egerod Israelsen, Eric Trépo, Aleksander Ahm Krag, Stefan Stender · 2025 · Seminars in Liver Disease
  93. Sex Differences in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Epidemiology, Pathophysiology, and Clinical Implications
    Kanica Kaushal, Smriti Singh, Ankita Anand, Gayatri Ramakrishna, Pratibha Ramchandra Kale, Rishabh Sharma, Bharat Bhushan Rewari, Shiv Kumar Sarin · 2026 · Journal of Clinical and Experimental Hepatology
  94. Non-alcoholic fatty liver disease and compromised endothelial function in people with type 2 diabetes
    Zeinab Montazeri, Nahid Hashemi‐Madani, Hamed Iraji, Masoudreza Sohrabi, Fariba Alaei-Shahmiri, Zahra Emami, Mohammad Reza Babaei, Mojtaba Malek, Mohammad E. Khamseh · 2023 · BMC Endocrine Disorders
  95. Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean
    Yun Hwan Oh, Seogsong Jeong, Sun Jae Park, Joseph C. Ahn, Sang Min Park · 2023 · Medicine
  96. Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD
    Mingqian Jiang, Ziyan Pan, Jacob George, Mohammed Eslam · 2024 · Hepatology International
  97. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism
    Songyao Liu, Eisuke Murakami, Takashi Nakahara, Kazuki Ohya, Yuji Teraoka, Grace Naswa Makokha, Takuro Uchida, Kei Morio, Hatsue Fujino, Atsushi Ono et al. · 2020 · Molecular Medicine Reports
  98. HCC in metabolic syndrome: current concepts and future directions
    Lucia Zampaglione, Jacopo Ferrari, Federica Pedica, Nicolas Goossens · 2021 · Hepatoma Research
  99. Molecular mechanisms of liver carcinogenesis related to metabolic syndrome
    C. Campani, J. Nault · 2022 · Hepatoma Research
  100. Evolution of Non-alcoholic Fatty Liver Disease to Liver Cancer: Insights from Genome-wide Association Studies
    Sathish Kumar Mungamuri, Yogendra Kumar Gupta, Padaki Nagaraja Rao, Bagepally Ravishankar · 2023 · Gene Expression